What drives such mass hype in Tcell Pd-1 k/o CRISPR clinical trials that 100% deaths in the Chinese trial does not make into a single article?

I am finding this quite perplexing actually (they dont even quote their own July 2019 story in Pultizer. Hmmm, maybe not with so much financial clout. Yesterday (Nov 7, 2019), there was a deluge of reports – “CRISPR-Edited T Cells Used in Cancer Patients for the First Time in the US”.

Not one of them mentioned that the first trial (which is similar in nature) in China has resulted in a disaster.

1. Jul 2018 they published data 10/21 people had died in a high (26) impact factor journal – 0 citations in 18 months

2. Dec 2018 – 19/21 people had died

3. Jul 2019 – 20/21 had died, Dr Wu wanted to publish, couldnt – and not work on CRISRP again

 

In fact, the Penn study will be worse since they use 3 gRNAs.  They found translocations – speaking of it as nothing abnormal (see image below)

Hyperprogression

Even without CRISPR, Tcell immunotherapy has a problem with hyperprogression – ie the tumors start growing at a rapid rate (20% according to this 2019 study). But adding CRIPSR makes it lethal – 100% deaths is not acceptable.

Whatever decisions patients take before enrolling in such trials, they should have full access to existing knowledge.

No wonder I cant even pre-print showing how dangerous CRISPR can be.